Sucrose

Summary

Sucrose (CHEMBL253582) is an approved small-molecule sweetening agent; indicated across 7 conditions including attention deficit-hyperactivity disorder and postural orthostatic tachycardia syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 7 conditions
• Chemistry: 342.3 Da · C12H22O11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL253582
Name	Sucrose
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	5988
ChEBI	CHEBI:17992
Molecular formula	C12H22O11
Molecular weight	342.3
InChIKey	CZMRCDWAGMRECN-UGDNZRGBSA-N

SMILES: C([C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)CO)O)O)CO)O)O)O)O

IUPAC name: (2R,3R,4S,5S,6R)-2-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

ChEBI definition: A glycosyl glycoside formed by glucose and fructose units joined by an acetal oxygen bridge from hemiacetal of glucose to the hemiketal of the fructose.

Pharmacological roles (ChEBI): osmolyte, sweetening agent.

Other ChEBI roles (chemical / environmental): human metabolite, algal metabolite, Saccharomyces cerevisiae metabolite, Escherichia coli metabolite, mouse metabolite.

Also known as: GNE-410, NSC-406942, S-67F, Sucrose, sucrose, SID26757665, SUCROSE, SUC, SID144208595, SID144205646, SID144210728

Patent coverage: 568,061 distinct patent families (1,554,524 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
attention deficit-hyperactivity disorder	2	MONDO:0007743	EFO:0003888
postural orthostatic tachycardia syndrome	2	MONDO:0011479	EFO:1000645
retinopathy of prematurity	1	MONDO:0006952	EFO:1001158
congestive heart failure	1	MONDO:0005009	EFO:0000373
acute respiratory distress syndrome	1	MONDO:0006502	EFO:1000637

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).